BriaCell Therapeutics Corp Ordinary Shares - New BCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
Trading Information
- Previous Close Price
- CA$4.66
- Day Range
- CA$4.34–4.45
- 52-Week Range
- CA$3.68–18.00
- Bid/Ask
- CA$4.18 / CA$5.50
- Shares Outstanding
- 8.73M
- Market Cap
- CA$38.42M
- Volume/Avg
- 1,305 / 6,974
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 31
- Website
- https://www.briacell.com
Valuation
Metric | BCT |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BCT
Financial Strength
Metric | BCT |
|---|---|
Quick Ratio | 2.66 |
Current Ratio | 2.76 |
Interest Coverage | −1,212.56 |
Quick Ratio
BCT
Profitability
Metric | BCT |
|---|---|
Return on Assets (Normalized) | −142.87% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −179.62% |
Return on Assets
BCT
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|pGZg#s% | LOCK|G>^? | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|cq@^mQv | LOCK|F!Wg> | $95B | |||
| Moderna Inc MRNA | LOCK|GCK$?P | LOCK|%< | $79B | |||
| argenx SE ADR ARGX | LOCK|s#j%&Qs | LOCK|pW | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|<^ZR?! | LOCK|^^ | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&f<!^m! | LOCK|zj>x^ | $30B | |||
| Incyte Corp INCY | LOCK|twbqV< | LOCK|N? | $23B | |||
| BioNTech SE ADR BNTX | LOCK|d&<yGn | LOCK|^!# | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|psQkWw$ | LOCK|pbr<@ | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|J>z?Y^P | LOCK|Hk | $15B |